PPBT - Multiplikator P/S Purple Biotech Corp
High clinical risks and the necessity of balancing R&D expenditures with equity issuances define the current profile of Purple Biotech (PPBT). Trial transparency and strict expense auditing ensure robust management. The company's P/S ratio reflects the business valuation relative to sales, where represents the current level of the metric. The firm's innovations are focused on combating tumor resistance through the development of targeted therapies.
Rincian analitis perusahaan Purple Biotech Corp (PPBT)
- rega saham lan prakiraan rega para ahli:
- statistik kapitalisasi pasar:
- data ekuitas miturut neraca:
- indikator beban kredit lan likuiditas emiten:
Utang marang Ekuitas Purple Biotech|PPBT - Utang jangka dawa marang modal|Kewajiban jangka cendhak marang modal Kitov Pharma|PPBT - Gunggung utang perusahaan|Rasio utang marang aset resik Purple Biotech Corp|PPBT - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Purple Biotech|Koefisien jangkoan perantara purple-biotech.com
- informasi bathi lan kelipatan valuasi:
PPBT - Bathi resik perusahaan|Bathi resik sing dikarepake Purple Biotech|PPBT - Koefisien rega marang bathi|Rasio kapitalisasi marang bathi mangsa ngarep Purple Biotech Ltd|PPBT - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Purple Biotech Corp|PPBT - Bathi operasional EBITDA|Bathi resik saben saham sajrone 12 wulan pungkasan Purple Biotech|PPBT - Bathi resik saben saham (EPS TTM)|Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan purple-biotech.com|PPBT - Wutah bathi saben saham ing taun lumaku|Prakiraan owah-owahan bathi resik saben saham kanggo taun ngarep Purple Biotech
- data total pendapatan lan volume dodolan:
Ringkesan analitik perusahaan:purple-biotech.com, PPBT
The P/S multiple determines the market value of one dollar of revenue, allowing for an assessment of the premium paid for an asset relative to its actual sales. By analyzing the price/sales multiple, an investor can determine the extent to which the current capitalization of Purple Biotech (PPBT) is justified by the commercialization of oncology drugs, including the potential market entry of CM24 antibodies for the therapy of pancreatic and gastric cancers.
Perusahaan pesaing
ONC: Rasio rega marang dodolan|Halozyme - Kapitalisasi marang pendapatan|Multiplikator P/S Revolution Medicines Inc RVMD|AAPG - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan CGON (CG Oncology Therapeutics)|UroGen Pharma Ltd. (URGN) - Rasio rega marang pendapatan|Rasio rega marang dodolan BCAX (bicara.com)|Rasio rega marang pendapatan Personalis|Rasio rega marang pendapatan ERAS|Multiplikator P/S DCTH|YMAB - Rega marang dodolan|Aura Biosciences, Inc. - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan CADL|Accuray - Multiplikator P/S|SLS: Rasio rega marang pendapatan|ACTU: Multiplikator P/S|CTOR - Koefisien rega marang pendapatan|Rasio rega marang pendapatan TuHURA Biosciences Inc.|Rega marang dodolan protaratx.com TARA|Kapitalisasi marang pendapatan FATE (Fate Therapeutics)|Kapitalisasi marang volume dodolan WHWK|Multiplikator P/S TCRX (TScan Therapeutics, Inc.)|Champions Oncology Inc (CSBR) - Rega marang dodolan|XBiotech USA - Multiplikator P/S|CEL-SCI Corporation (CVM) - Kapitalisasi marang pendapatan|OSTX: Multiplikator P/S|radiopharmtheranostics.com - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Artiva Biotherapeutics Inc.|Adlai Nortye Limited - Rasio rega marang dodolan|Rasio rega marang pendapatan Veru Inc. (VERU)|TPST: Rasio rega marang dodolan|Multiplikator P/S XLO (Xilio Therapeutics)|Renovaro Biosciences - Rasio rega marang pendapatan|MURA: Kapitalisasi marang pendapatan|Kairos Pharma Ltd - Kapitalisasi marang volume dodolan|OKUR: Multiplikator P/S|Kapitalisasi marang pendapatan CytoMed Therapeutics Limited|CRIS (Curis Inc.) - Multiplikator P/S|Multiplikator P/S Apollomics Corp|Rasio rega marang pendapatan Tharimmune Corp (THAR)|advanbiomed.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S GNPX (Genprex, Inc.)|CLDI - Kapitalisasi marang pendapatan|Sunshine Biopharma, Inc. - Multiplikator P/S|Rega marang dodolan Xenetic Biosciences|Salarius (SLRX) - Rasio rega marang pendapatan|American Oncology Network, Inc. - Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan BGNE|CKPT: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ELEV|Kapitalisasi marang pendapatan icadmed.com ICAD|Ikena Oncology - Kapitalisasi marang pendapatan|Multiplikator P/S Notable Labs Corp NTBL|VIRX - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan MOR (morphosys.com)|NAYA: Multiplikator P/S|Rega marang dodolan Ascentage Pharma Group International (AAPGV)
